Scientific American reports on three paths to rescheduling of psilocybin. The first is legislative, going through congress. The second route is administrative, via Biden and the DEA (least likely route). And the third route is judicial, suing the DEA after the second route fails.
Compound Psilocybin
Visit article
Category Popular Press
Published in Scientific American
Article Author
Mason MarksMason Marks is an assistant professor of law at the University of New Hampshire Franklin Pierce School of Law. He is a senior fellow and project lead of the Project on Psychedelics Law and Regulation (POPLAR) at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School. In 2021, he was appointed to the Oregon Psilocybin Advisory Board, which advises the Oregon Health Authority on rules for the state's emerging psilocybin industry.